ClinicalTrials.gg
Active, not recruitingNCT04531917BCS-PAINUpdated Mar 16, 2026

The Effect of Pain Neuroscience Education and Behavioural Graded Activity on Chronic Pain in Breast Cancer Survivors

An interventional study of Pain Neuroscience Education and Behavioural Graded Activity in Breast Neoplasms, Survivors and Chronic Pain, sponsored by Universitair Ziekenhuis Brussel. Active, not recruiting at 1 site in Belgium. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Breast Neoplasms by Universitair Ziekenhuis Brussel — 3 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · Universitair Ziekenhuis Brussel.

Started
2020
the only one that year
No phase
3 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Breast Neoplasms by Universitair Ziekenhuis Brussel, this one is the only one that started in 2020, is one of 3 with no phase, and was the 5th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 10 studies in Breast Neoplasms by Universitair Ziekenhuis Brussel are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Breast Neoplasms by Universitair Ziekenhuis Brussel, or all of them as a file.
02

Study summary

Chronic pain in breast cancer survivors (BCS) is of considerable concern as it impacts the health-related quality of life (HRQoL) and activities of daily living negatively. Over the past decades, awareness has raised the value of pain neuroscience education (PNE) in chronic pain. However, pain education remains underused in oncology and is often restricted to a biomedical management, which falls short in explaining persistent pain following cancer. Since PNE alone has rather small effect sizes, it should ideally be combined with a physical part, 'behavioural graded activity' (BGA). Therefore, the purpose of this study is to investigate the effectiveness of PNE with BGA compared to usual care on chronic pain in BCS.

A multi-centre, parallel, two-arm, double-blinded superiority with a three months intervention and two years follow-up will be conducted in 200 BCS with chronic pain. These will be randomly assigned to the intervention or usual care group. The intervention group will receive 6 sessions, in which PNE and BGA will be integrated. Whereas, the usual care group will receive an information leaflet regarding "Pain in and after cancer".

The primary objective of the present study is to examine whether the combination of PNE and BGA has an added value in decreasing the pain intensity compared to the usual care in BCS with chronic pain. The secondary objectives are to investigate whether the combination of PNE and BGA has the ability to reduce endogenous hyperalgesia and improve HRQoL compared to the usual care in BCS with chronic pain.

03

Conditions studied

  • Breast Neoplasms
  • Survivors
  • Chronic Pain

Keywords

  • Behavioural Graded Activity
  • Pain Neuroscience Education
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To meet the definition introduced by the National Cancer Institute's Office of Cancer Survivorship, in which a cancer survivor is a patient with a history of cancer that is beyond the acute diagnosis and treatment phase. Patients need to be cancer-free and should have finished their primary treatment with a curative intent for at least 3 months prior to study participation. hormonal therapy and immunotherapy form the exception to the rule and are tolerated.
  • To report a pain severity of at least 3 out of 10 on pain visual analogue scale.
  • To be able to speak and read in Dutch in order to give and to complete the assessment tools. Written and signed consent will be obtained from all participants.

Exclusion criteria

Exclusion Criteria:

  • Suffering from dementia or cognitive impairment (unable to understand the test instructions and/or score \<23/30).
  • Suffering from severe psychological or psychiatric diseases.
  • Diagnosis of new neoplasms or .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Pain Neuroscience Education + Behavioural Graded Activity

    Patients allocated to the intervention group will receive a 12-week treatment program that consists of 6 sessions, in which 'Pain Neuroscience Education' and 'Behavioural Graded Activity' will be integrated.

    Other: Pain Neuroscience Education · Other: Behavioural Graded Activity

  • Active comparator
    Usual care

    Patients allocated to the control group will receive an information leaflet from "Kom op tegen kanker" regarding "Pain in and after cancer".

    Other: Usual care

Interventions

  • OtherPain Neuroscience Education

    Pain Neuroscience Education (PNE) teaches patients about complex pain mechanisms known to be of importance in pain following breast cancer such as malfunctioning of the endogenous analgesic system and pain memories.

  • OtherBehavioural Graded Activity

    Patients in the experimental group will receive a behavioural treatment integrated within the concepts of operant conditioning. The purpose of Behavioural Graded Activity (BGA) is to increase the level of physical activity in the patient's daily lives in a time-contingent manner. On top of that, a healthy behaviour will be positively reinforced to consequently create a withdrawal of the attention towards pain behaviour, which is seen as an unreliable "alarm sign" in chronic pain patients. The implementation of BGA after PNE is described in the guideline reported by the International Association for the Study of Pain.

  • OtherUsual care

    The content of the leaflet has a biomedical approach in explaining pain and providing information on the different pain medication classes. This leaflet is mostly available in waiting rooms of oncology centres and units of the Flemish part of Belgium.

06

What researchers measure

Primary outcomes

  1. Change in pain intensity and pain interference

    Change between baseline (T1) and 3 months post-intervention (T3) * Measured with the 'Brief Pain Inventory' * The minimum and maximum values: 0, 10 * Higher score means a worse outcome

    Time frame: T1: baseline (within one week before randomisation) and T3: 3 months after intervention (w 26)

  2. Self-reported pain intensity and pain interference

    * Measured with the 'Brief Pain Inventory' * The minimum and maximum values: 0, 10 * Higher score means a worse outcome

    Time frame: T1: baseline (within one week before randomisation)

  3. Self-reported pain intensity and pain interference

    * Measured with the 'Brief Pain Inventory' * The minimum and maximum values: 0, 10 * Higher score means a worse outcome

    Time frame: T2: after finishing intervention (week 13)

  4. Self-reported pain intensity and pain interference

    * Measured with the 'Brief Pain Inventory' * The minimum and maximum values: 0, 10 * Higher score means a worse outcome

    Time frame: T3: 3 months after intervention (week 26)

  5. Self-reported pain intensity and pain interference

    * Measured with the 'Brief Pain Inventory' * The minimum and maximum values: 0, 10 * Higher score means a worse outcome

    Time frame: T4: 1 year after intervention (week 64)

  6. Self-reported pain intensity and pain interference

    * Measured with the 'Brief Pain Inventory' * The minimum and maximum values: 0, 10 * Higher score means a worse outcome

    Time frame: T5: 2 years after intervention (week 116)

Secondary outcomes

  1. Self-reported health-related quality of life

    * Measured with the 'European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30)' * The minimum and maximum values: 0, 100 * Higher score means a better outcome

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  2. Temperature detection threshold

    Assessed by the Medoc TSA-II Neurosensory Analyzer.

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13) and T3: 3 months after intervention (w 26)

  3. Pain detection threshold

    Assessed by the digital algometer, the Medoc TSA-II Neurosensory Analyzer and a manual blood pressure cuff.

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13) and T3: 3 months after intervention (w 26)

  4. Pain tolerance threshold

    Assessed by a manual blood pressure cuff.

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13) and T3: 3 months after intervention (w 26)

  5. Endogenous pain inhibition

    Assessed objectively by conditioned pain modulation paradigm. A manual blood pressure is the conditioned stimulus, and the digital algometer and the Medoc TSA-II Neurosensory Analyzer are testing stimuli.

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13) and T3: 3 months after intervention (w 26)

  6. Endogenous pain facilitation

    Assessed objectively by temporal summation paradigm. Ten testing stimuli will be applied, and subjects will be asked to rate their pain intensity on the first, fifth and tenth stimulus by using the Visual Analogue Scale.

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13) and T3: 3 months after intervention (w 26)

Other outcomes

  1. Self-reported pain

    * Measured with the 'Visual Analogue Scale' * The minimum and maximum values: 0mm, 100mm * Higher score means a worse outcome

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  2. Self-reported neuropathic pain

    * Measured with the 'Douleur Neuropatique 4' * The minimum and maximum values: 0, 10 * Higher score means a worse outcome * A score of 4 or higher indicates neuropathic pain

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  3. Self-reported central sensitization

    * Measured with the 'Central Sensitization Index' * The minimum and maximum values: 0, 100 * Higher score means a worse outcome * A score of 40 or higher indicates the presence of central sensitization

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  4. Self-reported physical activity level

    * Measured with the 'International Physical Activity Questionnaire short form' * Total physical activity in MET-min/week and time spent sitting

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  5. Self-reported physical activity level

    * Measured with the 'logbook' * Subjects enrolled in the intervention arm will have to fill in the logbook on daily basis.

    Time frame: During the intervention and T2: after finishing intervention (w 13)

  6. Self-reported sleep quality

    * Measured with the 'Pittsburgh Sleep Quality Index' * The minimum and maximum values: 0, 21 * Higher score means a worse outcome * A scores above 5 indicates poor global sleep quality

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  7. Self-reported insomnia severity

    * Measured with the 'Insomnia Severity Index' * The minimum and maximum values: 0, 28 * Higher score means a worse outcome * A scores of 8 or higher indicates insomnia

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  8. Self-reported fatigue

    * Measured with the 'Fatigue Severity Scale' * The minimum and maximum values: 9, 63 * Higher score means a worse outcome

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  9. Self-reported pain cognitions (pain catastrophizing)

    * Measured with the 'Pain Catastrophizing Scale' * The minimum and maximum values: 0, 52 * Higher score means a worse outcome * A scores of 30 or higher indicates pain catastrophizing thoughts

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  10. Self-reported pain cognitions (perceived injustice)

    * Measured with the 'Injustice Experience Questionnaire' * The minimum and maximum values: 0, 48 * Higher score means a worse outcome

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  11. Self-reported pain cognitions (illness perception)

    * Measured with the 'the Brief Illness Perception Questionnaire' * The minimum and maximum values: 0, 10 * Higher score means a worse outcome

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  12. Self-reported pain cognitions (pain vigilance and awareness)

    * Measured with the 'Pain Vigilance and Awareness questionnaire' * The minimum and maximum values: 0, 90 * Higher score means a worse outcome

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  13. Self-reported depression

    * Measured with the 'Depression, Anxiety, Stress Scale' * The minimum and maximum values: 0, 21 * Higher score means a worse outcome

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  14. Self-reported anxiety

    * Measured with the 'Depression, Anxiety, Stress Scale' * The minimum and maximum values: 0, 21 * Higher score means a worse outcome

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  15. Self-reported stress

    * Measured with the 'Depression, Anxiety, Stress Scale' * The minimum and maximum values: 0, 21 * Higher score means a worse outcome

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  16. Treatment adherence

    Patient adherence for the treatment sessions will be calculated as the ratio of the number of treatment sessions that were actually carried out versus the number of prescribed sessions.

    Time frame: During the intervention and T2: after finishing intervention (w 13)

  17. Treatment compliance

    Compliance will be calculated as the ratio of the total training duration (recorded in the logbooks) versus the prescribed total training duration, multiplied by 100.

    Time frame: During the intervention and T2: after finishing intervention (w 13)

  18. The presence of axillary web syndrome

    The diagnosis of Axillary Web Syndrome (AWS) will be made clinically. * Scored on 5-point Likert scale (totally disagree, disagree, don't disagree/agree, agree, totally agree) * The presence of rope-like cords in the axilla to the wrist is assessed by inspection and/or palpation.

    Time frame: T1: baseline (within one week before randomisation)

  19. The presence of lymphedema

    Lymphedema will be clinically diagnosed: The Stemmer sign is positive if the assessor is unable to pinch (between his/her thumb and index finger) the dorsal skin of proximal phalanx (second or third finger). A positive test confirms the presence of primary and secondary lymphedema of the arm(s). Single circumference measurement will only be performed if unilateral lymphedema is suspected. The arm circumference will be measured by a nylon tape measure with an accuracy of 1mm. The tape measure will be placed around the arm without tightening the tape at 30cm above the styloid process. Lymphedema is present if there is at least a difference of 10% between both arms.

    Time frame: T1: baseline (within one week before randomisation)

  20. The presence of arthralgia

    To assess arthralgia the assessor will ask the patient two questions: "Do you experience symmetrical pain in the left and right shoulders, elbows, wrists, fingers, hips, knees, ankles and/or toes?" and "Do you experience morning stiffness? And if so, for how many minutes?"

    Time frame: T1: baseline (within one week before randomisation)

  21. Detection of inflammation or adhesion of the scar tissue

    The scar tissue will be clinically scored. First, the assessor will inspect the affected (and painful) region for possible skin damage and will be looking for: wound disruption, hematoma (bruising), abscess (cavity filled with pus) and seroma (cavity filled with transparent liquid). Second, the he will inspect the presence of a possible inflammation process of the scar tissue and will be looking for signs such as: warmth, redness, etc. Third, he will assess the mobility of the scar. During this manual test, will be assessed whether the scar is moving relative to the underlying layers, which will be scored on a 5-point Likert scale with response possibilities: (totally disagree, disagree, don't disagree/agree, agree, totally agree).

    Time frame: T1: baseline (within one week before randomisation)

  22. Self-reported health care cost

    * Measured with the 'Medical Consumption Questionnaire' * 38 questions to quantify the direct medical costs of a patients' total medical consumption, encompassing additional diagnostics, consultations, surgery including stay in hospitals, physiotherapy, medication and aids prescribed by the general practitioner as well as medication and aids purchased by the patients themselves.

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  23. Self-reported work absenteeism and productivity loss at work

    * Measured with the 'Productivity Cost Questionnaire' * 20 questions to quantify the indirect costs outside health care but related to the disease (e.g. the costs due to absence of work and possible decreased productivity losses of paid and unpaid work).

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  24. Self-reported overall health status

    * Measured with the 'EuroQol 5D instrument (EQ-5D-5L)' * 5 dimensions scored on a 5-Likert scale and visual analogue scale (0 to 100) * Higher score means a better outcome

    Time frame: T1: baseline (within one week before randomisation), T2: after finishing intervention (w 13), T3: 3 months after intervention (w 26), T4: 1 year after intervention (w 64) and T5: 2 years after intervention (w 116)

  25. Patient specific questionnaire

    Self-administered questions about: gender, ethnicity, age, nationality, weight, height, civil state, mutuality, educational level, year of the breast cancer diagnosis, received breast cancer treatments, lymphedema, medication, other treatments, menopausal, hot flashes.

    Time frame: T1: baseline (within one week before randomisation)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Dec 2026, 74 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 74 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2020
First posted
Aug 31, 2020
StartActual
Oct 12, 2020
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04531917
Collaborators
Fund for Scientific Research, Flanders, Belgium, Vrije Universiteit Brussel
Responsible party
Sponsor
First posted
Aug 31, 2020
Start date
Oct 12, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Mar 16, 2026

Study contacts

Jo Nijs, Prof.
principal investigator · Vrije Universiteit Brussel

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion